1. Home
  2. AEAQ vs CDXS Comparison

AEAQ vs CDXS Comparison

Compare AEAQ & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEAQ

Activate Energy Acquisition Corp. Class A Ordinary Share

N/A

Current Price

$9.96

Market Cap

312.2M

Sector

N/A

ML Signal

N/A

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$2.46

Market Cap

256.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEAQ
CDXS
Founded
2025
2002
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
312.2M
256.3M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
AEAQ
CDXS
Price
$9.96
$2.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.0K
1.2M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.82
EPS
N/A
N/A
Revenue
N/A
$138,590,000.00
Revenue This Year
N/A
$7.73
Revenue Next Year
N/A
$14.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.30
52 Week Low
$9.87
$0.96
52 Week High
$9.98
$3.87

Technical Indicators

Market Signals
Indicator
AEAQ
CDXS
Relative Strength Index (RSI) 56.05 49.63
Support Level $9.88 $2.40
Resistance Level $9.98 $2.67
Average True Range (ATR) 0.01 0.22
MACD -0.00 -0.06
Stochastic Oscillator 71.43 17.46

Price Performance

Historical Comparison
AEAQ
CDXS

About AEAQ Activate Energy Acquisition Corp. Class A Ordinary Share

Activate Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: